ClinicalTrials.gg
CompletedNCT05413369Updated Sep 24, 2025Results posted

iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)

A Phase 3 interventional study of Insulin glargine/Lixisenatide and IDegAsp in Type 2 Diabetes Mellitus, sponsored by Sanofi. Completed at 60 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-24.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
582
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.

Enrollment
35th of 175
582 · median 253
Started
2022
with 6 others
Phase 3
60 of 176
1 open now
Registered
164th of 176
by date
Lead sponsor
82 of 176
Sanofi

Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 35th largest by enrollment of the 175 interventional ones that give a count, is one of 7 that started in 2022, is one of 60 in phase 3, and was the 164th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This was a parallel-group treatment, Phase 3, randomized, 2-arm study that assessed the efficacy and safety of iGlarLixi to IDegAsp in Chinese T2DM participants insufficiently controlled with oral antidiabetic drug(s).

Study details included:

  • Study duration per participant: approximately up to 27 weeks
  • Treatment duration: 24 weeks
  • Visit frequency: after screening (an on-site visit), on-site or phone call visit every 1 week from randomization till Week 4, every 2 weeks till week 12 and then every 3 weeks till Week 24 (End of Treatment). There were 14 visits that included 7 phone calls and 7 on-site visits in total during screening and treatment periods. There was a safety follow-up by a phone call visit (End of Study) in 3 days after the last dose of the treatment.
  • Health measurement/Observation: change in HbA1c as the primary endpoint.
  • Intervention name: iGlarLixi and IDegAsp
  • Participant sex: male and female
  • Participant age range: adults at least 18 years of age
  • Condition/disease: Type 2 diabetes mellitus
Read the detailed description

27 weeks

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant had at least 18 of age inclusive, at the time of signing the .
  • Participants who were diagnosed with T2DM for at least 1 year before the screening visit
  • Participants who were treated for at least 3 months prior to the screening visit with a stable dose of metformin (at least 1000 mg/day or the maximum tolerated dose) alone or in combination with a second oral antidiabetic treatment that can be a sulfonylurea (SU), a glinide, an alpha-glucosidase inhibitor (alpha-GI), a dipeptidyl-peptidase-4 (DPP-4) inhibitor or a sodium-glucose co-transporter 2 (SGLT-2) inhibitor
  • at screening visit:

    • between 7.5% and 11%, both inclusive, for participants previously treated with metformin alone or + SGLT-2 inhibitor, or
    • between 7.0% and 10%, both inclusive, for participants previously treated with metformin + a second oral antidiabetic treatment other than SGLT-2 inhibitor.
  • Participants who were overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
  • (BMI) \<40 kg/m² at screening
  • Male or female, including females of who agreed to use during the study duration
  • Participants were capable of giving signed informed consent as described in Appendix 1 of the protocol which included compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion criteria

Exclusion Criteria:

  • Participant who had a severe renal function impairment with an estimated (eGFR) \<30 mL/min/1.73 m²
  • Pregnant or breast-feeding woman.
  • Woman of not protected by highly effective method of birth control and/or who is unwilling or unable to be tested for pregnancy
  • Conditions/situations such as:

    • Participant with short .
    • Participant with conditions/concomitant diseases making him/her not evaluable for the primary efficacy endpoint (eg, hemoglobinopathy or hemolytic anemia, receipt of blood or plasma products within 3 months prior to screening).
    • Participant with conditions/concomitant diseases precluding his/her safe participation in this study (eg, active malignant tumor, major systemic diseases, presence of diabetic retinopathy or presence of macular edema likely to require laser treatment within the study period).
    • Uncooperative or any condition that could make the participant potentially non-compliant to the study procedures (e.g., participant unable or unwilling to do self-injections or blood glucose monitoring using the Sponsor-provided blood glucometer at home).
  • Previous treatment with insulin (except for short-term treatment ≤14 days due to intercurrent illness at the discretion of the Investigator) within 1 year prior to screening.
  • Use of oral or injectable glucose-lowering agents other than those stated in the inclusion criteria within 3 months prior to screening.
  • Use of systemic (excluding topical application or inhaled forms) for 1 week or more within 3 months prior to screening.
  • Use of weight loss drugs within 3 months prior to screening.
  • History of discontinuation of a previous treatment with GLP-1 RAs due to safety/tolerability reasons or lack of efficacy.
  • Use of any drug other than specified in this protocol within 1 month or 5 half-lives, whichever is longer, prior to screening.
  • Laboratory findings tested at the screening visit:

    • Amylase and/or lipase >3 times the (ULN) laboratory range.
    • (ALT) or aspartate aminotransferase (AST) >3 ULN.
    • Total >1.5 ULN (except in case of Gilbert's syndrome).
    • Calcitonin ≥20 pg/mL (5.9 pmol/L).
    • \<10.5 g/dL and/or neutrophils \<1500/mm\^3 and/or \<100 000/mm\^3.
    • Positive urine pregnancy test in female of childbearing potential.
  • to metformin and/or SGLT-2 inhibitor use, for those who were taking it prior to the study, according to local labeling, warning/precaution of use (when appropriate) as displayed in the respective National regulation
  • Individuals accommodated in an institution because of regulatory or legal order; prisoners or participants who are legally institutionalized
  • Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures
  • Participants are employees of the clinical study site or other individuals directly involved in the conduct of the study, or immediate family members of such individuals (in conjunction with section 1.61 of the ICH-GCP Ordinance E6)
  • Any specific situation during study implementation/course that may raise ethics considerations
  • Sensitivity to any of the study interventions (insulin or, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study
  • Participants who withdrawn consent at randomization or were lost to follow up at randomization visit.

The above information was not intended to contain all considerations relevant to a potential participation in a clinical trial.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
582 participants (actual)

Study arms

  • Experimental
    iGlarLixi

    Participants self-administered iGlarLixi (100 units per milliliter \[U/mL\] insulin glargine + 100 or 50 microgram \[mcg\]/mL lixisenatide respectively) subcutaneous (SC) injection once daily on top of metformin +/- sodium-glucose co-transporter 2 inhibitor (SGLT-2i) for 24 weeks. Dose was individually adjusted.

    Drug: Insulin glargine/Lixisenatide · Drug: Metformin · Drug: SGLT2 inhibitor

  • Active comparator
    IDegAsp

    Participants self-administered IDegAsp (100 U/mL of insulin degludec + insulin aspart with a ratio of 70:30) SC injection once daily on top of metformin +/- SGLT-2i for 24 weeks. Dose was individually adjusted.

    Drug: IDegAsp · Drug: Metformin · Drug: SGLT2 inhibitor

Interventions

06

What researchers measure

Primary outcomes

  1. Change in HbA1c From Baseline to Week 24: Non-Inferiority Analysis

    Blood samples were collected at indicated timepoints for analysis of HbA1c. Baseline was defined as the last available pre-dose assessment (on or before Day 1).

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Change in HbA1c From Baseline to Week 24: Superiority Analysis

    Blood samples were collected at indicated timepoints for analysis of HbA1c. Baseline was defined as the last available pre-dose assessment (on or before Day 1).

    Time frame: Baseline, Week 24

  2. Change in Body Weight From Baseline to Week 24

    Body weight was obtained with the participant wearing undergarments or very light clothing and no shoes, and with an empty bladder. The same scale was used throughout the study. Baseline was defined as the last available pre-dose assessment (on or before Day 1).

    Time frame: Baseline, Week 24

  3. Percentage of Participants Reaching HbA1c <7% at Week 24

    Blood samples were collected at indicated timepoints for analysis of HbA1c. Participants without Week 24 HbA1c value were considered as non-responders. Percentages are rounded off to the tenth decimal place.

    Time frame: Week 24

  4. Percentage of Participants Reaching HbA1c <7% With no Body Weight Gain at Week 24

    Blood samples were collected at indicated timepoints for analysis of HbA1c. Participants without Week 24 HbA1c or body weight value were considered as non-responders. Percentages are rounded off to the tenth decimal place.

    Time frame: Week 24

  5. Percentage of Participants Reaching HbA1c <7% With no Body Weight Gain at Week 24 and no Hypoglycemia During 24-Week Treatment Period

    Blood samples were collected at indicated timepoints for analysis of HbA1c. Participants without Week 24 HbA1c or body weight value were considered as non-responders. During the study, participants were instructed to document the presence of hypoglycemic episodes in their study diary. Hypoglycemia was characterized as per American Diabetes Association (ADA) 2021 recommendations. * ADA Level 1 hypoglycemia: A measurable glucose concentration \<70 milligram/deciliter (mg/dL) (3.9 millimoles/liter \[mmol/L\]) but \>=54 mg/dL (3.0 mmol/L). * ADA Level 2 hypoglycemia: Blood glucose concentration \<54 mg/dL \[3.0 mmol/L\]; the threshold at which neuroglycopenic symptoms begin to occur and requires immediate action to resolve the hypoglycemic event. * ADA Level 3 hypoglycemia: A severe event characterized by altered mental and/or physical functioning that requires assistance from another person for recovery. Percentages are rounded off to the tenth decimal place.

    Time frame: Baseline up to Week 24

  6. Change in Fasting Plasma Glucose From Baseline to Week 24

    Blood samples were collected at fasting state (no food or drinks \[except water\] for at least 8 hours) at indicated timepoints. Baseline was defined as the last available pre-dose assessment (on or before Day 1).

    Time frame: Baseline, Week 24

  7. Change in Average 7-Point Self-Monitored Plasma Glucose (SMPG) Profile From Baseline to Week 24

    Participants were provided with a glucometer, corresponding supplies, a leaflet, and with diaries in order to perform self-measurement of plasma glucose and its recording and were trained on how to use the glucometer. The 7-point SMPG profile was measured at the following 7-points: pre-prandial (before starting a meal) and 2 hours postprandial each for breakfast, lunch, dinner and at bedtime. Two hours postprandial (breakfast, lunch and dinner) was defined as 2 hours after the start of the meal. The participants performed 7-point SMPG profile measurement over a single 24-hour period on 2 different days in the week. Baseline was defined as the last available pre-dose assessment (on or before Day 1).

    Time frame: Baseline, Week 24

  8. Percentage of Participants Reaching HbA1c <7% at Week 24 With no Hypoglycemia During 24-Week Treatment Period

    Blood samples were collected at indicated timepoints for analysis of HbA1c. Participants without Week 24 HbA1c value were considered as non-responders. Hypoglycemia was characterized as per ADA 2021 recommendations. * ADA Level 1 hypoglycemia: A measurable glucose concentration \<70 mg/dL (3.9 mmol/L) but \>=54 mg/dL (3.0 mmol/L). * ADA Level 2 hypoglycemia: Blood glucose concentration \<54mg/dL \[3.0 mmol/L\]; the threshold at which neuroglycopenic symptoms begin to occur and requires immediate action to resolve the hypoglycemic event. * ADA Level 3 hypoglycemia: A severe event characterized by altered mental and/or physical functioning that requires assistance from another person for recovery. Percentages are rounded off to the tenth decimal place.

    Time frame: Baseline up to Week 24

  9. Percentage of Participants Reaching HbA1c <7% at Week 24 With no Clinically Relevant Hypoglycemia During 24-Week Treatment Period

    Blood samples were collected at indicated timepoints for analysis of HbA1c. Participants without Week 24 HbA1c value were considered as non-responders. Participants who reached the specified target of HbA1c without any clinically significant symptoms of hypoglycemia as defined in ADA Levels 2 or 3 are reported. Percentages are rounded off to the tenth decimal place.

    Time frame: Baseline up to Week 24

  10. Total Daily Insulin Dose at Week 24

    Total daily insulin dose was defined as the sum of the insulin dose from study treatment and non-study treatment (e.g., rescue therapy). It was the average of the last 3 available insulin doses recorded in the electronic case report form in the week before visit.

    Time frame: Week 24

  11. Percentage of Participants Who Required Rescue Therapy During the 24-Week Treatment Period

    Routine HbA1c value was used to determine the requirement of rescue medication. Threshold value was HbA1c \>8% at Week 12 or later on despite appropriate corrective actions. Percentages are rounded off to the tenth decimal place.

    Time frame: Baseline up to Week 24

  12. Change in Fasting C-Peptide From Baseline to Week 24

    Blood samples were collected at fasting state (no food or drinks \[except water\] for at least 8 hours) at indicated timepoints. Baseline was defined as the last available pre-dose assessment (on or before Day 1).

    Time frame: Baseline, Week 24

  13. Number of Participants With Any Hypoglycemia Event During On-Treatment Period

    During the study, participants were instructed to document the presence of hypoglycemic episodes in their study diary. Number of participants who met ADA definition of hypoglycemia during the treatment period are reported. * ADA Level 1 hypoglycemia: A measurable glucose concentration \<70 mg/dL (3.9 mmol/L) but \>=54 mg/dL (3.0 mmol/L). * ADA Level 2 hypoglycemia: Blood glucose concentration \<54mg/dL \[3.0 mmol/L\]; the threshold at which neuroglycopenic symptoms begin to occur and requires immediate action to resolve the hypoglycemic event. * ADA Level 3 hypoglycemia: A severe event characterized by altered mental and/or physical functioning that requires assistance from another person for recovery. The on-treatment period (ie, treatment-emergent \[TE\] period) was defined as the period from the first injection study treatment to the last injection of study treatment + 3 days (1 day for hypoglycemia).

    Time frame: From first dose of study drug up to 1 day after the last administration of study drug (maximum treatment exposure: 192 days)

  14. Hypoglycemic Event Rate During the On-Treatment Period

    During the study, participants were instructed to document the presence of hypoglycemic episodes in their study diary. Percentage of hypoglycemic events per participant-year during on-treatment period are reported. The on-treatment period (TE period) was defined as the period from the first injection study treatment to the last injection of study treatment + 3 days (1 day for hypoglycemia).

    Time frame: From first dose of study drug up to 1 day after the last administration of study drug (maximum treatment exposure: 192 days)

  15. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), Adverse Events Of Special Interest (AESIs) and TEAEs Leading to Treatment Discontinuation

    An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any adverse event that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was a suspected transmission of any infectious agent via an authorized medicinal product. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required. TE period was defined as the period from the first injection study treatment to the last injection of study treatment + 3 days.

    Time frame: From signature of the informed consent form up to the final visit regardless of seriousness or relationship to study drug (maximum treatment exposure: 192 days)

  16. Number of Participants With Potentially Clinically Significant Laboratory Abnormalities (PCSA): Vital Signs

    Vital signs assessments included systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) in sitting position with their arm outstretched in line with mid-sternum and supported and weight. Criteria for PCSA: SBP: \<=95 millimeters of mercury (mmHg) and decrease from baseline \>=20 mmHg, \>=160 mmHg and increase from baseline \>=20 mmHg; DBP :\<=45 mmHg and decrease from baseline \>=10 mmHg,\>=110 mmHg and increase from baseline \>=10 mmHg; HR: \<=50 beats/min and decrease from baseline \>=20 beats/min,\>=120 beats/min and increase from baseline \>=20 beats/min; Weight \>=5% decrease from baseline, \>=5% increase from baseline.

    Time frame: From first dose of study drug up to 3 days after last administration of study drug (maximum treatment exposure: 192 days)

  17. Number of Participants With Potentially Clinically Significant Laboratory Abnormalities (PCSA): Hematology

    Criteria for PCSA: For Hemoglobin (Hb), there are 3 criteria: (1)\<=115 grams (g)/L (Male\[M\]) or \<=95 g/L (Female\[F\]), (2)\>= 185 g/L (M) or \>=165 g/L (F), and (3) decrease from baseline \>=20 g/L; Hematocrit: \<=0.37 volume/volume (v/v) (M) or \<=0.32 v/v (F), \>=0.55 v/v (M) or \>=0.5 v/v (F); Red blood cells (RBC): \>=6 Tera/L; Platelets: \<100 Giga/L, \>=700 Giga/L; White blood cells (WBC): \<3.0 Giga/L (Non-Black \[NB\]); \<2.0 Giga/L (Black \[B\]) or \>=16.0 Giga/L; Neutrophils: \<1.5 Giga/L (NB) or \<1.0 Giga/L (B); Lymphocytes: \>4.0 Giga/L; Monocytes: \>0.7 Giga/L; Basophils: \>0.1 Giga/L; Eosinophils: \>0.5 Giga/L or \>upper limit of normal (ULN) (if ULN \>=0.5 Giga/L).

    Time frame: From first dose of study drug up to 3 days after last administration of study drug (maximum treatment exposure: 192 days)

  18. Number of Participants With Potentially Clinically Significant Laboratory Abnormalities (PCSA): Clinical Chemistry

    Criteria for PCSA: Lipase: \>=3 ULN; Amylase: \>=3 ULN; Sodium: \<=129 mmol/L; \>=160 mmol/L; Potassium: \<3 mmol/L, \>=5.5 mmol/L; Creatinine: \>=150 micromoles per liter (umol/L), \>=30% or \>=100% change from baseline; Glomerular filtration rate (GFR): \>=60-\<90 mL/minute(min)/1.73 square meter (m\^2) (mild decrease in GFR), \>=30-\<60 mL/min/1.73m\^2 (moderate decrease in GFR), \>=15-\<30 mL/min/1.73m\^2 (severe decrease in GFR),\<15 mL/min/1.73m\^2 (end stage renal disease); Creatinine clearance (CG): \>=60-\<90 mL/min (mild decrease in GFR), \>=30-\<60 mL/min (moderate decrease in GFR), \>=15-\<30 mL/min (severe decrease in GFR), \<15 mL/min (end stage renal disease); Urea nitrogen (BUN): \>=17 mmol/L and Uric acid: \<120 or \>408 umol/L; Alanine transaminase (ALT) and aspartate transaminase (AST): \>3/5/10/20 ULN. Alkaline phosphatase:\>1.5 ULN, total bilirubin (TBILI): \>1.5 or \>2 ULN, ALT and TBILI:\> ALT\>3ULN and TBILI \>2 ULN and Conjugated and total bilirubin: \>35% TBILI and TBILI \>1.5 ULN.

    Time frame: From first dose of study drug up to 3 days after last administration of study drug (maximum treatment exposure: 192 days)

07

Results

Posted Oct 30, 2024

Participant flow

The study was conducted at 60 centers in China. A total of 733 participants were screened between 07-Jul-2022 and 17-Apr-2023, of which 151 were screen failures. Screen failures were mainly due to not meeting eligibility criteria.

Participant flow — Overall Study
MilestoneiGlarLixiIDegAsp
Started291291
Randomized and treated290291
Completed 24-week treatment period272284
Completed274284
Not completed177
Withdrew: Adverse event11
Withdrew: Withdrawal by subject134
Withdrew: Non-compliance with study schedule21
Withdrew: Other11

Outcome measures

PrimaryChange in HbA1c From Baseline to Week 24: Non-Inferiority Analysis

Blood samples were collected at indicated timepoints for analysis of HbA1c. Baseline was defined as the last available pre-dose assessment (on or before Day 1).

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percentage of HbA1c
Change in HbA1c From Baseline to Week 24: Non-Inferiority Analysis
percentage of HbA1ciGlarLixiIDegAsp
Change in HbA1c From Baseline to Week 24: Non-Inferiority Analysis-1.88 ± 0.05-1.68 ± 0.05
Statistical analysis
  • iGlarLixi vs IDegAsp · ANCOVA · p = <0.001 · Least squares (ls) mean difference: -0.20 · 95% CI -0.33 to -0.07Treatment groups and randomization stratum of previous oral anti-diabetic drug(OADs) as fixed effects,and baseline HbA1c continuous value as covariate
SecondaryChange in HbA1c From Baseline to Week 24: Superiority Analysis

Blood samples were collected at indicated timepoints for analysis of HbA1c. Baseline was defined as the last available pre-dose assessment (on or before Day 1).

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percentage of HbA1c
Change in HbA1c From Baseline to Week 24: Superiority Analysis
percentage of HbA1ciGlarLixiIDegAsp
Change in HbA1c From Baseline to Week 24: Superiority Analysis-1.88 ± 0.05-1.68 ± 0.05
Statistical analysis
  • iGlarLixi vs IDegAsp · ANCOVA · p = 0.003 · Ls mean difference: -0.20 · 97.5% CI -0.35 to -0.05Treatment groups and randomization stratum of previous as fixed effects, and baseline HbA1c continuous value as covariate
SecondaryChange in Body Weight From Baseline to Week 24

Body weight was obtained with the participant wearing undergarments or very light clothing and no shoes, and with an empty bladder. The same scale was used throughout the study. Baseline was defined as the last available pre-dose assessment (on or before Day 1).

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · kilogram
Change in Body Weight From Baseline to Week 24
kilogramiGlarLixiIDegAsp
Change in Body Weight From Baseline to Week 24-0.30 ± 0.291.19 ± 0.25
Statistical analysis
  • iGlarLixi vs IDegAsp · ANCOVA · p = <0.001 · Ls mean difference: -1.49 · 97.5% CI -2.32 to -0.66Treatment groups, randomization stratums of HbA1c and previous OADs as fixed effects, and baseline body weight continuous value as covariate.
SecondaryPercentage of Participants Reaching HbA1c <7% at Week 24

Blood samples were collected at indicated timepoints for analysis of HbA1c. Participants without Week 24 HbA1c value were considered as non-responders. Percentages are rounded off to the tenth decimal place.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Reaching HbA1c <7% at Week 24
percentage of participantsiGlarLixiIDegAsp
Percentage of Participants Reaching HbA1c <7% at Week 2472.559.8
Statistical analysis
  • iGlarLixi vs IDegAsp · Regression, Logistic · p = <0.001 · Odds ratio (or): 1.89 · 97.5% CI 1.25 to 2.85Adjusted for treatment group, randomization stratum of previous OADs, and continuous baseline value of HbA1c
SecondaryPercentage of Participants Reaching HbA1c <7% With no Body Weight Gain at Week 24

Blood samples were collected at indicated timepoints for analysis of HbA1c. Participants without Week 24 HbA1c or body weight value were considered as non-responders. Percentages are rounded off to the tenth decimal place.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Reaching HbA1c <7% With no Body Weight Gain at Week 24
percentage of participantsiGlarLixiIDegAsp
Percentage of Participants Reaching HbA1c <7% With no Body Weight Gain at Week 2440.521.3
Statistical analysis
  • iGlarLixi vs IDegAsp · Regression, Logistic · p = <0.001 · Odds ratio (or): 2.59 · 95% CI 1.79 to 3.76Adjusted for treatment group, randomization stratum of previous OADs, and continuous baseline value of HbA1c and body weight.
SecondaryPercentage of Participants Reaching HbA1c <7% With no Body Weight Gain at Week 24 and no Hypoglycemia During 24-Week Treatment Period

Blood samples were collected at indicated timepoints for analysis of HbA1c. Participants without Week 24 HbA1c or body weight value were considered as non-responders. During the study, participants were instructed to document the presence of hypoglycemic episodes in their study diary. Hypoglycemia was characterized as per American Diabetes Association (ADA) 2021 recommendations. * ADA Level 1 hypoglycemia: A measurable glucose concentration \<70 milligram/deciliter (mg/dL) (3.9 millimoles/liter \[mmol/L\]) but \>=54 mg/dL (3.0 mmol/L). * ADA Level 2 hypoglycemia: Blood glucose concentration \<54 mg/dL \[3.0 mmol/L\]; the threshold at which neuroglycopenic symptoms begin to occur and requires immediate action to resolve the hypoglycemic event. * ADA Level 3 hypoglycemia: A severe event characterized by altered mental and/or physical functioning that requires assistance from another person for recovery. Percentages are rounded off to the tenth decimal place.

Time frame:
Baseline up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Reaching HbA1c <7% With no Body Weight Gain at Week 24 and no Hypoglycemia During 24-Week Treatment Period
percentage of participantsiGlarLixiIDegAsp
Percentage of Participants Reaching HbA1c <7% With no Body Weight Gain at Week 24 and no Hypoglycemia During 24-Week Treatment Period26.513.4
Statistical analysis
  • iGlarLixi vs IDegAsp · Regression, Logistic · p = <0.001 · Odds ratio (or): 2.34 · 95% CI 1.52 to 3.60Adjusted for treatment group, randomization stratum of previous OADs, and continuous baseline value of HbA1c and body weight.
SecondaryChange in Fasting Plasma Glucose From Baseline to Week 24

Blood samples were collected at fasting state (no food or drinks \[except water\] for at least 8 hours) at indicated timepoints. Baseline was defined as the last available pre-dose assessment (on or before Day 1).

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · mmol/L
Change in Fasting Plasma Glucose From Baseline to Week 24
mmol/LiGlarLixiIDegAsp
Change in Fasting Plasma Glucose From Baseline to Week 24-3.18 ± 0.11-3.45 ± 0.11
SecondaryChange in Average 7-Point Self-Monitored Plasma Glucose (SMPG) Profile From Baseline to Week 24

Participants were provided with a glucometer, corresponding supplies, a leaflet, and with diaries in order to perform self-measurement of plasma glucose and its recording and were trained on how to use the glucometer. The 7-point SMPG profile was measured at the following 7-points: pre-prandial (before starting a meal) and 2 hours postprandial each for breakfast, lunch, dinner and at bedtime. Two hours postprandial (breakfast, lunch and dinner) was defined as 2 hours after the start of the meal. The participants performed 7-point SMPG profile measurement over a single 24-hour period on 2 different days in the week. Baseline was defined as the last available pre-dose assessment (on or before Day 1).

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · mmol/L
Change in Average 7-Point Self-Monitored Plasma Glucose (SMPG) Profile From Baseline to Week 24
mmol/LiGlarLixiIDegAsp
Change in Average 7-Point Self-Monitored Plasma Glucose (SMPG) Profile From Baseline to Week 24-3.36 ± 0.12-2.92 ± 0.11
SecondaryPercentage of Participants Reaching HbA1c <7% at Week 24 With no Hypoglycemia During 24-Week Treatment Period

Blood samples were collected at indicated timepoints for analysis of HbA1c. Participants without Week 24 HbA1c value were considered as non-responders. Hypoglycemia was characterized as per ADA 2021 recommendations. * ADA Level 1 hypoglycemia: A measurable glucose concentration \<70 mg/dL (3.9 mmol/L) but \>=54 mg/dL (3.0 mmol/L). * ADA Level 2 hypoglycemia: Blood glucose concentration \<54mg/dL \[3.0 mmol/L\]; the threshold at which neuroglycopenic symptoms begin to occur and requires immediate action to resolve the hypoglycemic event. * ADA Level 3 hypoglycemia: A severe event characterized by altered mental and/or physical functioning that requires assistance from another person for recovery. Percentages are rounded off to the tenth decimal place.

Time frame:
Baseline up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Reaching HbA1c <7% at Week 24 With no Hypoglycemia During 24-Week Treatment Period
percentage of participantsiGlarLixiIDegAsp
Percentage of Participants Reaching HbA1c <7% at Week 24 With no Hypoglycemia During 24-Week Treatment Period43.635.7
SecondaryPercentage of Participants Reaching HbA1c <7% at Week 24 With no Clinically Relevant Hypoglycemia During 24-Week Treatment Period

Blood samples were collected at indicated timepoints for analysis of HbA1c. Participants without Week 24 HbA1c value were considered as non-responders. Participants who reached the specified target of HbA1c without any clinically significant symptoms of hypoglycemia as defined in ADA Levels 2 or 3 are reported. Percentages are rounded off to the tenth decimal place.

Time frame:
Baseline up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Reaching HbA1c <7% at Week 24 With no Clinically Relevant Hypoglycemia During 24-Week Treatment Period
percentage of participantsiGlarLixiIDegAsp
Percentage of Participants Reaching HbA1c <7% at Week 24 With no Clinically Relevant Hypoglycemia During 24-Week Treatment Period66.756.0
SecondaryTotal Daily Insulin Dose at Week 24

Total daily insulin dose was defined as the sum of the insulin dose from study treatment and non-study treatment (e.g., rescue therapy). It was the average of the last 3 available insulin doses recorded in the electronic case report form in the week before visit.

Time frame:
Week 24
Reported as:
Least squares mean · units
Total Daily Insulin Dose at Week 24
unitsiGlarLixiIDegAsp
Total Daily Insulin Dose at Week 2427.68 ± 0.8433.78 ± 0.83
SecondaryPercentage of Participants Who Required Rescue Therapy During the 24-Week Treatment Period

Routine HbA1c value was used to determine the requirement of rescue medication. Threshold value was HbA1c \>8% at Week 12 or later on despite appropriate corrective actions. Percentages are rounded off to the tenth decimal place.

Time frame:
Baseline up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Required Rescue Therapy During the 24-Week Treatment Period
percentage of participantsiGlarLixiIDegAsp
Percentage of Participants Who Required Rescue Therapy During the 24-Week Treatment Period5.26.9
SecondaryChange in Fasting C-Peptide From Baseline to Week 24

Blood samples were collected at fasting state (no food or drinks \[except water\] for at least 8 hours) at indicated timepoints. Baseline was defined as the last available pre-dose assessment (on or before Day 1).

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · nanomoles/liter (nmol/L)
Change in Fasting C-Peptide From Baseline to Week 24
nanomoles/liter (nmol/L)iGlarLixiIDegAsp
Change in Fasting C-Peptide From Baseline to Week 24-0.23 ± 0.02-0.33 ± 0.02
SecondaryNumber of Participants With Any Hypoglycemia Event During On-Treatment Period

During the study, participants were instructed to document the presence of hypoglycemic episodes in their study diary. Number of participants who met ADA definition of hypoglycemia during the treatment period are reported. * ADA Level 1 hypoglycemia: A measurable glucose concentration \<70 mg/dL (3.9 mmol/L) but \>=54 mg/dL (3.0 mmol/L). * ADA Level 2 hypoglycemia: Blood glucose concentration \<54mg/dL \[3.0 mmol/L\]; the threshold at which neuroglycopenic symptoms begin to occur and requires immediate action to resolve the hypoglycemic event. * ADA Level 3 hypoglycemia: A severe event characterized by altered mental and/or physical functioning that requires assistance from another person for recovery. The on-treatment period (ie, treatment-emergent \[TE\] period) was defined as the period from the first injection study treatment to the last injection of study treatment + 3 days (1 day for hypoglycemia).

Time frame:
From first dose of study drug up to 1 day after the last administration of study drug (maximum treatment exposure: 192 days)
Reported as:
Count of participants · Participants
Number of Participants With Any Hypoglycemia Event During On-Treatment Period
ParticipantsiGlarLixiIDegAsp
Number of Participants With Any Hypoglycemia Event During On-Treatment Period102118
SecondaryHypoglycemic Event Rate During the On-Treatment Period

During the study, participants were instructed to document the presence of hypoglycemic episodes in their study diary. Percentage of hypoglycemic events per participant-year during on-treatment period are reported. The on-treatment period (TE period) was defined as the period from the first injection study treatment to the last injection of study treatment + 3 days (1 day for hypoglycemia).

Time frame:
From first dose of study drug up to 1 day after the last administration of study drug (maximum treatment exposure: 192 days)
Reported as:
Number · event rate per participant-year
Hypoglycemic Event Rate During the On-Treatment Period
event rate per participant-yeariGlarLixiIDegAsp
Hypoglycemic Event Rate During the On-Treatment Period1.902.72
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), Adverse Events Of Special Interest (AESIs) and TEAEs Leading to Treatment Discontinuation

An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any adverse event that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was a suspected transmission of any infectious agent via an authorized medicinal product. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required. TE period was defined as the period from the first injection study treatment to the last injection of study treatment + 3 days.

Time frame:
From signature of the informed consent form up to the final visit regardless of seriousness or relationship to study drug (maximum treatment exposure: 192 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), Adverse Events Of Special Interest (AESIs) and TEAEs Leading to Treatment Discontinuation
ParticipantsiGlarLixiIDegAsp
Any TEAE220192
Any TESAE1512
Any AESI62
Any TEAE leading to treatment discontinuation71
SecondaryNumber of Participants With Potentially Clinically Significant Laboratory Abnormalities (PCSA): Vital Signs

Vital signs assessments included systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) in sitting position with their arm outstretched in line with mid-sternum and supported and weight. Criteria for PCSA: SBP: \<=95 millimeters of mercury (mmHg) and decrease from baseline \>=20 mmHg, \>=160 mmHg and increase from baseline \>=20 mmHg; DBP :\<=45 mmHg and decrease from baseline \>=10 mmHg,\>=110 mmHg and increase from baseline \>=10 mmHg; HR: \<=50 beats/min and decrease from baseline \>=20 beats/min,\>=120 beats/min and increase from baseline \>=20 beats/min; Weight \>=5% decrease from baseline, \>=5% increase from baseline.

Time frame:
From first dose of study drug up to 3 days after last administration of study drug (maximum treatment exposure: 192 days)
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities (PCSA): Vital Signs
ParticipantsiGlarLixiIDegAsp
SBP: <=95 mmHg and decrease from baseline >=20 mmHg11
SBP: >=160 mmHg and increase from baseline >=20 mmHg47
DBP :<=45 mmHg and decrease from baseline >=10 mmHg00
DBP: >=110 mmHg and increase from baseline >=10 mmHg00
HR: <=50 beats/min and decrease from baseline >=20 beats/min00
HR: >=120 beats/min and increase from baseline >=20 beats/min00
Weight: >=5% decrease from baseline4119
Weight: >=5% increase from baseline2973
SecondaryNumber of Participants With Potentially Clinically Significant Laboratory Abnormalities (PCSA): Hematology

Criteria for PCSA: For Hemoglobin (Hb), there are 3 criteria: (1)\<=115 grams (g)/L (Male\[M\]) or \<=95 g/L (Female\[F\]), (2)\>= 185 g/L (M) or \>=165 g/L (F), and (3) decrease from baseline \>=20 g/L; Hematocrit: \<=0.37 volume/volume (v/v) (M) or \<=0.32 v/v (F), \>=0.55 v/v (M) or \>=0.5 v/v (F); Red blood cells (RBC): \>=6 Tera/L; Platelets: \<100 Giga/L, \>=700 Giga/L; White blood cells (WBC): \<3.0 Giga/L (Non-Black \[NB\]); \<2.0 Giga/L (Black \[B\]) or \>=16.0 Giga/L; Neutrophils: \<1.5 Giga/L (NB) or \<1.0 Giga/L (B); Lymphocytes: \>4.0 Giga/L; Monocytes: \>0.7 Giga/L; Basophils: \>0.1 Giga/L; Eosinophils: \>0.5 Giga/L or \>upper limit of normal (ULN) (if ULN \>=0.5 Giga/L).

Time frame:
From first dose of study drug up to 3 days after last administration of study drug (maximum treatment exposure: 192 days)
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities (PCSA): Hematology
ParticipantsiGlarLixiIDegAsp
Hb: <=115 g/L (M); <=95 g/L (F)41
Hb: >=185 g/L (M); >=165 g/L (F)14
Hb: Decrease from Baseline >=20 g/L2519
Hematocrit: <=0.37 v/v (M) or <=0.32 v/v (F)26
Hematocrit: >=0.55 v/v (M) or >=0.5 v/v (F)3730
RBC: >=6 Tera/L56
Platelets: <100 Giga/L37
Platelets: >=700 Giga/L00
WBC: <3.0 Giga/L (NB); < 2.0 Giga/L (B)23
WBC: >=16.0 Giga/L10
Neutrophils: <1.5 Giga/L (NB) or <1.0 Giga/L (B)57
Lymphocytes: > 4.0 Giga/L46
Monocytes: >0.7 Giga/L3529
Basophils: >0.1 Giga/L25
Eosinophils: >0.5 Giga/L or >ULN22
SecondaryNumber of Participants With Potentially Clinically Significant Laboratory Abnormalities (PCSA): Clinical Chemistry

Criteria for PCSA: Lipase: \>=3 ULN; Amylase: \>=3 ULN; Sodium: \<=129 mmol/L; \>=160 mmol/L; Potassium: \<3 mmol/L, \>=5.5 mmol/L; Creatinine: \>=150 micromoles per liter (umol/L), \>=30% or \>=100% change from baseline; Glomerular filtration rate (GFR): \>=60-\<90 mL/minute(min)/1.73 square meter (m\^2) (mild decrease in GFR), \>=30-\<60 mL/min/1.73m\^2 (moderate decrease in GFR), \>=15-\<30 mL/min/1.73m\^2 (severe decrease in GFR),\<15 mL/min/1.73m\^2 (end stage renal disease); Creatinine clearance (CG): \>=60-\<90 mL/min (mild decrease in GFR), \>=30-\<60 mL/min (moderate decrease in GFR), \>=15-\<30 mL/min (severe decrease in GFR), \<15 mL/min (end stage renal disease); Urea nitrogen (BUN): \>=17 mmol/L and Uric acid: \<120 or \>408 umol/L; Alanine transaminase (ALT) and aspartate transaminase (AST): \>3/5/10/20 ULN. Alkaline phosphatase:\>1.5 ULN, total bilirubin (TBILI): \>1.5 or \>2 ULN, ALT and TBILI:\> ALT\>3ULN and TBILI \>2 ULN and Conjugated and total bilirubin: \>35% TBILI and TBILI \>1.5 ULN.

Time frame:
From first dose of study drug up to 3 days after last administration of study drug (maximum treatment exposure: 192 days)
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities (PCSA): Clinical Chemistry
ParticipantsiGlarLixiIDegAsp
Lipase: >=3 ULN69
Amylase: >=3 ULN00
Sodium: <=129 mmol/L00
Sodium: >=160 mmol/L00
Potassium: <3 mmol/L00
Potassium: >=5.5 mmol/L13
Creatinine: >=150 umol/L01
Creatinine: >=30% change from baseline3629
Creatinine: >=100% change from baseline01
GFR: Mild decrease in GFR8079
GFR: Moderate decrease in GFR1111
GFR: Severe decrease in GFR01
GFR: End stage renal disease00
CG: Mild decrease in GFR8085
CG: Moderate decrease in GFR1216
CG: Severe decrease in GFR00
CG: End stage renal disease00
BUN: >=17 mmol/L00
Uric Acid: <120 umol/L00
Uric Acid: >408 umol/L104108
ALT: >3 ULN42
ALT: >5 ULN10
ALT: >10 ULN10
ALT: >20 ULN00
AST: >3 ULN00
AST: >5 ULN10
AST: >10 ULN00
AST: >20 ULN00
Alkaline Phosphatase: >1.5 ULN25
TBILI: >1.5 ULN31
TBILI: >2 ULN10
ALT>3ULN and TBILI >2 ULN00
Conjugated and TBILI: >35% TBILI and TBILI >1.5 ULN20

Adverse events

Collected over From signature of the informed consent form up to the final visit regardless of seriousness or relationship to study drug (maximum treatment exposure: 192 days). All-cause mortality was collected throughout the study, up to 67 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
iGlarLixi0/290 (0%)15/290 (5.2%)152/290 (52.4%)
IDegAsp0/291 (0%)12/291 (4.1%)101/291 (34.7%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventiGlarLixiIDegAsp
Cerebral InfarctionNervous system disorders2/2901/291
Bronchopulmonary AspergillosisInfections and infestations1/2900/291
PneumoniaInfections and infestations1/2900/291
Ischaemic Cerebral InfarctionNervous system disorders1/2900/291
Vertebrobasilar InsufficiencyNervous system disorders1/2900/291
CataractEye disorders1/2900/291
Sudden Hearing LossEar and labyrinth disorders1/2900/291
Coronary Artery DiseaseCardiac disorders1/2900/291
Myocardial IschaemiaCardiac disorders1/2901/291
Lung DisorderRespiratory, thoracic and mediastinal disorders1/2900/291
Most frequent other events
Most frequent other events
EventiGlarLixiIDegAsp
Upper Respiratory Tract InfectionInfections and infestations50/29037/291
Covid-19Infections and infestations39/29031/291
NauseaGastrointestinal disorders35/2902/291
HyperuricaemiaMetabolism and nutrition disorders26/29024/291
DizzinessNervous system disorders19/2905/291
Lipase IncreasedInvestigations19/29016/291
DiarrhoeaGastrointestinal disorders16/2907/291
VomitingGastrointestinal disorders15/2900/291

Baseline characteristics

Baseline characteristics were assessed for all randomized population.

Age, Continuous
Age, Continuous(years)iGlarLixiIDegAspTotal
Mean56.3 ± 10.257.5 ± 9.956.9 ± 10.0
Sex: Female, Male
Sex: Female, Male(Participants)iGlarLixiIDegAspTotal
Female141136277
Male150155305
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)iGlarLixiIDegAspTotal
Asian291291582
Glycated Hemoglobin (HbA1c)
Glycated Hemoglobin (HbA1c)(percentage of HbA1c)iGlarLixiIDegAspTotal
Mean8.58 ± 0.938.53 ± 0.908.55 ± 0.91
Duration of type 2 diabetes
Duration of type 2 diabetes(years)iGlarLixiIDegAspTotal
Mean8.56 ± 5.689.06 ± 6.008.81 ± 5.84
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms/square meter (kg/m^2))iGlarLixiIDegAspTotal
Mean25.92 ± 3.4725.42 ± 3.2525.67 ± 3.37
Randomization stratum of oral antidiabetic (OAD) (s) use at screening
Randomization stratum of oral antidiabetic (OAD) (s) use at screening(Participants)iGlarLixiIDegAspTotal
Metformin ± SGLT-2i151151302
Metformin + other OAD140140280
Prior use of SGLT-2i373774
08

Study locations

60 sites
  • Investigational Site Number : 1560008
    Baotou, 014010, China
  • Investigational Site Number : 1560001
    Beijing, 100853, China
  • Investigational Site Number : 1560027
    Beijing, 101200, China
  • Investigational Site Number : 1560019
    Beijing, China
  • Investigational Site Number : 1560023
    Cangzhou, 061000, China
  • Investigational Site Number : 1560059
    Changchun, 130021, China
  • Investigational Site Number : 1560046
    Changchun, 130041, China
  • Investigational Site Number : 1560052
    Changde, 415000, China
  • Investigational Site Number : 1560011
    Changsha, 410013, China
  • Investigational Site Number : 1560054
    Chengdu, 610081, China
  • Investigational Site Number : 1560024
    Chengdu, 611130, China
  • Investigational Site Number : 1560004
    Chenzhou, China
  • Investigational Site Number : 1560044
    Chongqing, 400010, China
  • Investigational Site Number : 1560053
    Dalian, 116011, China
  • Investigational Site Number : 1560030
    Foshan, 528399, China
  • Investigational Site Number : 1560043
    Guangzhou, 510080, China
  • Investigational Site Number : 1560029
    Guangzhou, 510150, China
  • Investigational Site Number : 1560021
    Handan, 056002, China
  • Investigational Site Number : 1560010
    Hangzhou, 310014, China
  • Investigational Site Number : 1560045
    Harbin, 150001, China
  • Investigational Site Number : 1560025
    Harbin, China
  • Investigational Site Number : 1560038
    Hohhot, China
  • Investigational Site Number : 1560056
    Huai'an, 223300, China
  • Investigational Site Number : 1560035
    Huanggang, 438000, China
  • Investigational Site Number : 1560055
    Huangshi, 435000, China
  • Investigational Site Number : 1560022
    Huizhou, 516001, China
  • Investigational Site Number : 1560051
    Huzhou, China
  • Investigational Site Number : 1560040
    Jinan, 250012, China
  • Investigational Site Number : 1560014
    Jinan, 250013, China
  • Investigational Site Number : 1560058
    Jingzhou, 434020, China
  • Investigational Site Number : 1560041
    Kaifeng, China
  • Investigational Site Number : 1560039
    Lanzhou, 730000, China
  • Investigational Site Number : 1560060
    Lianyungang, 222002, China
  • Investigational Site Number : 1560031
    Luoyang, 471003, China
  • Investigational Site Number : 1560028
    Nanjing, 210011, China
  • Investigational Site Number : 1560017
    Nanjing, China
  • Investigational Site Number : 1560018
    Nanjing, China
  • Investigational Site Number : 1560057
    Nantong, 226001, China
  • Investigational Site Number : 1560037
    Pingxiang, 337055, China
  • Investigational Site Number : 1560048
    Qingdao, 266042, China
  • Investigational Site Number : 1560012
    Qinhuangdao, China
  • Investigational Site Number : 1560003
    Shanghai, 200040, China
  • Investigational Site Number : 1560020
    Shanghai, 200040, China
  • Investigational Site Number : 1560007
    Shanghai, 201700, China
  • Investigational Site Number : 1560006
    Shanghai, China
  • Investigational Site Number : 1560009
    Shenyang, 110004, China
  • Investigational Site Number : 1560050
    Suzhou, China
  • Investigational Site Number : 1560016
    Tianjin, 300052, China
  • Investigational Site Number : 1560013
    Tianjin, 300121, China
  • Investigational Site Number : 1560047
    Tonghua, 130000, China
  • Investigational Site Number : 1560042
    Xingtai, 054031, China
  • Investigational Site Number : 1560015
    Xuzhou, China
  • Investigational Site Number : 1560033
    Yueyang, 414000, China
  • Investigational Site Number : 1560032
    Yueyang, China
  • Investigational Site Number : 1560026
    Yuncheng, 044000, China
  • Investigational Site Number : 1560049
    Zhengzhou, China
  • Investigational Site Number : 1560034
    Zhenjiang, 212001, China
  • Investigational Site Number : 1560036
    Zhongshan, China
  • Investigational Site Number : 1560005
    Zhuzhou, 412007, China
  • Investigational Site Number : 1560002
    Zigong, 643002, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Oct 2023, 15 months.

Results were first posted in Oct 2024, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 15 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2022
First posted
Jun 10, 2022
StartActual
Jul 7, 2022
Primary completionActual
Oct 20, 2023
CompletionActual
Oct 20, 2023
Results first posted
Oct 30, 2024
Last update
Sep 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05413369
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jun 10, 2022
Start date
Jul 7, 2022
Primary completion
Oct 20, 2023
Completion
Oct 20, 2023
Results posted
Oct 30, 2024
Last update
Sep 24, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Glargine · Lixisenatide

Start the discussion